로딩 중…
지수 로딩 중…
Iovance Biotherapeutics, Inc.
IOVA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.32+6.02%
2026-08-03
Financials
Valuation Metrics
Iovance Biotherapeutics, Inc.'s Market Cap is $1.93B. At end of 2025 it was $1.11B. Ranked #2078 of 3,112 in US market (top 67%), #800 of 1,445 on NASDAQ (top 55%), #139 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.93B | US#2,078/3,112 Sec#139/269 |
| Revenue | $286M | US#2,579/3,112 Sec#101/269 |
| Net Income | $-354M | US—/3,112 Sec—/269 |
| Total Assets | $926M | US#2,478/3,112 Sec#102/269 |
| Net Assets | $722M | US#1,990/3,112 Sec#76/269 |
| Value | ||
| P/B | 2.67x | US#1,539/3,112 Sec#78/269 |
| P/S | 6.75x | US#2,480/3,112 Sec#103/269 |
| FCF Yield | -15.83% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -49.03% | US#2,736/3,112 Sec#171/269 |
| ROA | -38.23% | US#2,920/3,112 Sec#187/269 |
| Op. Margin | -127.16% | US#2,834/3,112 Sec#127/269 |
| Revenue Growth | 44.82% | US#334/3,112 Sec#56/269 |
| Financial Health | ||
| Debt Ratio | 28.25% | US#304/3,112 Sec#100/269 |
| Total Debt | $48M | US#2,555/3,112 Sec#149/269 |
| FCF | $-305M | US#2,790/3,112 Sec#242/269 |
| Cash | $197M | US#1,743/3,112 Sec#118/269 |
| Current Ratio | 3.60x | US#640/3,112 Sec#175/269 |
| Performance | ||
| 1Y Return | 61.01% | US#709/3,112 Sec#115/269 |
| 1M Return | 0.12% | US#1,631/3,112 Sec#73/269 |
| From 52W High | -23.49% | US#1,878/3,112 Sec#128/269 |
| 1Y MDD | -54.41% | US#2,552/3,112 Sec#197/269 |
| Trading | ||
| Volume | 12,998,577 shares | US#121/3,112 Sec#8/269 |
| Trading Value | $55M | US#1,296/3,112 Sec#76/269 |
| Per Share | ||
| EPS | $-0.96 | US—/3,112 Sec—/269 |
| BPS | $1.72 | US#2,542/3,112 Sec#185/269 |